Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Immunome, Inc.NASDAQ: IMNM
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses growth accelerates
Q3 FY2026 operating expenses of $90.36M rose 725.6% year over year, ahead of the +54.6% change in trailing-twelve-month operating expenses. Sequentially, it rose 15.6% from the prior quarter. Over 3 fiscal years it compounded at +80.8% a year.
Context
- Operating expenses amounted to 3142.2% of revenue in FY2025, down 340.2 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +725.6% holds above the trailing-twelve-month pace of +54.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 218.1M USD
- Year-over-year change
- -30.7%
- 4-year CAGR
- +71.5%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 218.1M | -30.7% |
| FY2024 | 2024-12-31 | 314.84M | +154.8% |
| FY2023 | 2023-12-31 | 123.55M | +234.8% |
| FY2022 | 2022-12-31 | 36.9M | +46.4% |
| FY2021 | 2021-12-31 | 25.2M | — |
Operating Expenses vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +54.6% is the 4th highest of 11, against a peer median of +34.3%.
- Over three fiscal years its annual growth of +80.8% compares with a peer median of +19.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $410.51M USD | +8.6% | +21.4% | 106.4% | |
| LTM Sep 2026 | $333.75M USD | +278.1% | +101.5% | 297994.6% | |
| LTM Sep 2026 | $299.94M USD | +54.6% | +80.8% | — | |
| LTM Mar 2026 | €250M EUR | +22.1% | +17.2% | 670.3% | |
| LTM Mar 2026 | $234.87M USD | +104.1% | +34.7% | 369.9% | |
| LTM Mar 2026 | $213.41M USD | -32.3% | +2.0% | 214.2% | |
| LTM Mar 2026 | $173.51M USD | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $156.87M USD | +11.7% | +68.8% | — | |
| LTM Mar 2026 | $47.9M USD | +53.4% | +9.6% | — | |
| LTM Sep 2026 | $39.45M USD | +46.4% | -12.9% | — | |
| LTM Mar 2026 | $35.95M USD | +65.2% | +48.4% | — | |
| Peer median (excluding IMNM) | — | +34.3% | +19.3% | 292.1% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.